As the calendar flips to the first full week of May, institutional focus is shifting from broad macroeconomic posturing toward idiosyncratic, company-level execution. For the week of May 4 through May 10, the catalyst calendar is dominated by earnings reports that will serve as referendums on pricing power, underwriting discipline, and post-crisis margin recoveries.
This week’s Scouter Top Ideas roadmap isolates three setups where the technical positioning has decoupled from recent fundamental disclosures. In Health Care, a medical device giant is attempting to shake off an oversold technical penalty; in Financials, a top-tier reinsurer is fighting the narrative that peak profitability has passed; and in Consumer Staples, a household name is trying to prove its margin turnaround is finally real.
Orthopedic Volumes Collide with Oversold Technicals
ZBH is scheduled to report Q1 2026 earnings on Tuesday, May 5, and the setup looks unusually mixed. The company said last week that elective procedure demand remained solid and raised its 2026 adjusted profit forecast , while the stock has recently traded near its 52-week low and appeared technically oversold.
The broader market has remained skeptical about joint-replacement volumes amid concern that GLP-1 obesity drugs could eventually weigh on procedure growth, but Zimmer Biomet’s recent reporting has pointed to resilient demand rather than a sharp slowdown. The company has described its operating performance as improving, though the exact pace of profit and revenue growth has varied by quarter.
Our catalyst models flag a 55% probability of a bullish outcome for this print. If management delivers another clean quarter with stable pricing and mix, ZBH could have room to re-rate higher, especially if investors become more comfortable with the outlook for procedure volumes and margins. The main downside risk would be any surprise slowdown in procedures or margin pressure tied to hospital capital constraints. Given the depressed starting valuation, expectations appear muted, leaving room for an upside surprise.
Pricing Discipline in the P&C Hard Market
In the reinsurance space, ACGL continues to operate as a low-multiple compounder. The company is scheduled to report its Q1 results and updated 2026 outlook on Wednesday, May 6 , making it an important read-through for the durability of property and casualty pricing.
Arch Capital reported strong 2025 results, and the stock has recently traded at a valuation below some broader insurance peers. That discount appears to reflect concern that underwriting margins could eventually normalize from cyclical highs.
The setup for Q1 carries a 60% bullish probability in our framework, eyeing a target of $98.00. The thesis relies on Arch showing that its underwriting results remain solid and that investment income continues to benefit from a higher-for-longer rate environment. Conversely, the bear case toward $89.00 hinges on any sign of reserve strengthening or commentary that suggests pricing momentum is moderating. The 1-standard-deviation expected move of $1.76 suggests the options market is currently underpricing the potential magnitude of this fundamental update.
Rebuilding Margins Under the Macro Microscope
Finally, CLX faces a pivotal Q3 FY26 earnings release on May 5. The household products manufacturer has been working through a difficult operating stretch, including a disrupted systems transition, raw input cost pressure, and investor scrutiny tied to securities-fraud allegations over past disclosures .
At roughly $87, CLX has looked technically oversold. The immediate question for Q3 is whether the company can halt its volume erosion and show that internal cost-savings programs are finally taking hold. Recent quarters have suggested some stabilization, with sequential improvement in earnings and a more constructive read on margins, though the volume picture remains an important watch item.
Because expectations have been reset lower, the print could still support an oversold bounce if results merely meet estimates and cost pressures appear contained. Our modeling sets a 52% probability of a bullish drift toward $95.50 over the subsequent week of digestion. However, consumer staples are unforgiving when pricing power fractures; a failure to show stabilized volumes or a negative update on input costs would likely keep pressure on the shares toward $82.50. For Clorox, Tuesday's release will be judged mostly on forward commentary and sequential margin progress rather than standard top-line variance.